Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS

FDA seeks advisory committee input on whether there is ‘convincing evidence’ to support regular approval for treatment of SOD1-ALS patients even though lone Phase III trial failed its primary endpoint; companies filed for accelerated approval on the basis that a reduction in plasma neurofilament light chain is reasonably likely to predict clinical benefit.

Two apples on table
Two approval scenarios are on the table for tofersen. • Source: Shutterstock

The US Food and Drug Administration will ask its external experts whether the existing data for Biogen, Inc. and Ionis Pharmaceuticals, Inc.’s Qalsody (tofersen) support either accelerated or regular approval for treatment of a subgroup of amyotrophic lateral sclerosis patients.

Biogen and Ionis are seeking accelerated approval on the basis that tofersen-driven reductions in plasma neurofilament light chain (NfL) are...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers